The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia

Authors: A. Oomen, Ilja; Verhagen, Marieke; Miranda, Mariarosaria; Allacher, Peter; Beckers, Erik A. M.; Blijlevens, Nicole M. A.; van der Bom, Johanna G; Coppens, Michiel; Driessens, Mariëtte; Eikenboom, Jeroen C. J.; Fijnvandraat, Karin; Hassan, Shermarke; van Heerde, Waander L.; Hooimeijer, H. Louise; Jansen, Joop H.; Kaijen, Paul; Leebeek, Frank W. G.; Meijer, Daniëlle; Paul, Helmut; Rijpma, Sanna R.; Rosendaal, Frits R.; Smit, Cees; van Vulpen, Lize F D; Voorberg, Jan; Schols, Saskia E. M.; Gouw, Samantha C.

Affiliations: Department of Pediatric Hematology, Amsterdam University Medical Center (UMC) Location University of Amsterdam, Amsterdam, Netherlands. Department of Molecular Hematology, Sanquin Research, Amsterdam, Netherlands. Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands. Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Nijmegen, Netherlands. Laboratory of Hematology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, Netherlands. Institute Krems Bioanalytics, International Management Center (IMC) University of Applied Sciences Krems, Krems, Austria. (…)

Publication: Frontiers in Immunology.

ABSTRACT: OBJECTIVES: Anti-factor VIII (FVIII) antibodies have been reported to exhibit both neutralizing and non-neutralizing characteristics. This is the first study investigating the full spectrum of FVIII-specific antibodies, including non-neutralizing antibodies, very-low titer inhibitors, and inhibitors, in a large nationwide population of persons with hemophilia A of all severities. METHODS: All persons with hemophilia A (mild (FVIII > 5-40 IU/dL)/moderate [FVIII 1-5 IU/dL)/severe (FVIII < 1 IU/dL)] with an available plasma sample who participated in the sixth Hemophilia in the Netherlands study between 2018 and 2019 were included. The presence of anti-FVIII antibodies of the immunoglobulin A, M, and G isotypes and IgG subclasses, along with antibody titer levels, were assessed using direct-binding ELISAs. FVIII specificity was assessed using a competition-based ELISA approach. The inhibitor status was determined using the Nijmegen ultra-sensitive Bethesda assay (NusBA) and the Nijmegen Bethesda assay (NBA). RESULTS: In total, 788 persons with hemophilia A (336 (42.6%) mild, 123 (15.6%) moderate, 329 (41.8%) severe hemophilia) were included. The median age was 45 years (IQR 24-60), and the majority (50.9%) had over 150 exposure days to FVIII concentrates. Within our population, 144 (18.3%) individuals had non-neutralizing FVIII-specific antibodies, 10 (1.3%) had very low-titer inhibitors (NusBA positive; NBA negative), and 13 (1.6%) had inhibitors (both NusBA and NBA positive). IgG1 was the most abundant FVIII-specific antibody subclass, and the highest titer levels were found for IgG4. In individuals without a reported history of inhibitor development, no clear differences were observed in antibody patterns between those who were minimally or highly exposed to FVIII concentrates. IgG4 subclass antibodies were only observed in persons with a reported history of FVIII inhibitor or in those with a currently detected (very low-titer) inhibitor. CONCLUSION: In this cross-sectional study, we identified non-neutralizing antibodies in a relatively large proportion of persons with hemophilia A. In contrast, in our population, consisting of persons highly exposed to FVIII concentrates, (very low-titer) inhibitors were detected only in a small proportion of persons, reflecting a well-tolerized population. Hence, our findings suggest that only a small subpopulation of non-neutralizing FVIII-specific antibodies is associated with clinically relevant inhibitors.